Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.90 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | SCD | O00767 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | FZD7 | O75084 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341776 | 0.91 | MAPT (0.89) | KDM4EMAPTGAALMNAALDH1A1 | |
| SCHEMBL3340070 | 0.88 | MAPT (0.78) | KDM4EMAPTGAALMNAALDH1A1 | |
| SCHEMBL3343782 | 0.88 | MAPT (0.78) | KDM4EMAPTGAALMNAALDH1A1 | |
| SCHEMBL3338748 | 0.87 | MAPT (0.82) | KDM4EMAPTGAALMNAALDH1A1 | |
| SCHEMBL3338134 | 0.86 | KDM4E (0.85) | KDM4EMAPTGAALMNAALDH1A1 | |
| SCHEMBL3341958 | 0.85 | MAPT (0.79) | KDM4EMAPTGAALMNAALDH1A1 | |
| SCHEMBL3336646 | 0.84 | KDM4E (0.76) | KDM4EMAPTGAALMNAALDH1A1 | |
| SCHEMBL3335920 | 0.83 | MAPT (0.71) | KDM4EMAPTGAALMNAALDH1A1 | |
| SCHEMBL3338655 | 0.82 | MAPT (0.82) | KDM4EMAPTGAALMNAALDH1A1 | |
| SCHEMBL3343901 | 0.82 | MEN1 (0.77) | KDM4EMAPTGAALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | TECHNISCHE UNIVERSITAT DARMSTADT (DE) | 2010-06-17 | — | — | US | claimed |
| US-8410152-B2 | Thiazolhydrazides for treatment of neurodegenerative diseases | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | TECHNISCHE UNIVERSITAT DARMSTADT (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | KDM4E 4489/4885MAPT 2/4885GAA 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.